Jens Renstrup Net Worth

Jens Renstrup biography

Dr. Jens Renstrup M.D. serves as Chief Medical Officer of the Company. Dr. Renstrup was Senior Vice President and Head of Global Medical Affairs at Alexion Pharmaceuticals, Inc. Prior to Alexion, Dr. Renstrup served as Head of Global Medical Affairs at GlaxoSmithKline from May 2010 to June 2015 and held various medical director positions at Merck & Co. from 2002 to 2010. Dr. Renstrup holds an M.D. from the University of Copenhagen and a graduate diploma in marketing from Copenhagen Business School.

What is the salary of Jens Renstrup?

As the Chief Medical Officer of SpringWorks Therapeutics, the total compensation of Jens Renstrup at SpringWorks Therapeutics is $575,795. There are 7 executives at SpringWorks Therapeutics getting paid more, with Saqib Islam having the highest compensation of $3,284,920.

How old is Jens Renstrup?

Jens Renstrup is 55, he's been the Chief Medical Officer of SpringWorks Therapeutics since 2017. There are 9 older and 9 younger executives at SpringWorks Therapeutics. The oldest executive at SpringWorks Therapeutics, Inc. is Freda Lewis-Hall, 65, who is the Independent Director.

What's Jens Renstrup's mailing address?

Jens's mailing address filed with the SEC is C/O SPRINGWORKS THERAPEUTICS, INC.,, 100 WASHINGTON BLVD., STAMFORD, CT, 06902.

Insiders trading at SpringWorks Therapeutics

Over the last 6 years, insiders at SpringWorks Therapeutics have traded over $386,249,433 worth of SpringWorks Therapeutics stock and bought 800,000 units worth $14,400,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Capital Life Sciences Inves... oraz Jeffrey Lawrence Schwartz. On average, SpringWorks Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $6,795,384. The most recent stock trade was executed by Saqib Islam on 3 September 2024, trading 49,000 units of SWTX stock currently worth $1,987,930.

What does SpringWorks Therapeutics do?

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

SpringWorks Therapeutics executives and stock owners

SpringWorks Therapeutics executives and other stock owners filed with the SEC include:

• Saqib Islam,
  Chief Executive Officer, Director
• Francis Perier,
  Chief Financial Officer
• Saqib Islam,
  CEO & Director
• Badreddin Edris,
  Chief Business Officer
• Dr. L. Mary Smith PH.D.,
  Chief Devel. Officer
• Dr. Badreddin Edris Ph.D.,
  Chief Operating Officer
• Francis I. Perier Jr., M.B.A.,
  Chief Financial Officer
• Jens Renstrup,
  Chief Medical Officer
• Herschel S. Weinstein J.D.,
  Gen. Counsel & Sec.
• Daniel Lynch,
  Independent Chairman of the Board
• Stephen Squinto,
  Acting Head of Research and Development, Director
• Daniel Pichl,
  Chief People Officer
• Jeffrey Schwartz,
  Independent Director
• Freda Lewis-Hall,
  Independent Director
• Alan Fuhrman,
  Independent Director
• Herschel Weinstein,
  General Counsel, Secretary
• L. Mary Smith,
  Senior Vice President - Clinical Research and Development
• Dr. Michael F. Burgess M.D., MBChB, Ph.D.,
  Head of R&D
• Bhavesh Ashar,
  Chief Commercial Officer
• Kim Diamond,
  VP of Communications & Investor Relations
• Michael P. Nofi,
  Chief Accounting Officer
• James Cassidy,
  Chief Medical Officer
• Carlos Alban,
  Director
• Julie Hambleton,
  Director
• Daniel Pichl,
  Chief People Officer
• Advisors Llc Orbi Med Capit...,
  
• Michael Nofi,
  Chief Accounting Officer
• Inc Pfizer Ventures (Us) Ll...,
  
• Capital Life Sciences Inves...,
  
• Bhavesh Ashar,
  Chief Commercial Officer
• Michael F. Burgess,
  Head of Research & Development
• Martin Mackay,
  Director
• Tai An Lin,
  Chief Scientific Officer